Sign in
TerminatedNo phase

Bronchial Asthma and Diabetes: Impact on Bronchial Inflammation and Exercise Capacity

Key facts

Who runs it
Istituti Clinici Scientifici Maugeri SpA
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
39 people enrolled
Started
10 Jul 2019
Ended
12 Jan 2024
Type of study
Observational, 3 groups
Treatments tested
  • data collection
Record updated
8 February 2024
Why it stopped
technical issue

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Diagnosis of bronchial asthma according to the GINA 2018 guideline
  • Clinical stability of asthmatic disease
  • Diagnosis of Type II diabetes according to the last Italian guidelines (1) and HbA1c < 9%, 54-75mmol/mol
  • Concomitant diagnosis of bronchial asthma (12) and diabetes according to the described guidelines
  • Age ≥18 years
  • Not-smokers, smokers or ex-smokers with pack/year ≤10
  • Patients able to collaborate in the required procedures and who have signed the informed consent

Who cannot take part

  • Bronchial asthma and/or diabetes with scarce clinical control
  • Diagnosis of cognitive impairment
  • Not able to carry out study procedures

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Type 2 diabetes is the most common form of diabetes and according to several studies, even lung can represent another target of the diabetic disease. Asthmatic patients often show comorbidities and obesity is one of the main.Several studies in literature suggest that patients with higher Body Mass Index (i.e. overweight and obese) have a greater risk of developing asthma compared to normal weight subjects. Considering inflammation, asthma is usually characterized by an increase of eosinophils in the airways and by a Th2 type inflammation, while a immunological type Th1 switch systemically characterizes diabetes. Even asthmatic patients, especially if diabetic, might have an increase of glucose in their airways, that could favourite or feed an inflammatory/infective state. Up to-day there are not in literature studies that have investigated the airways inflammatory pattern and the exercise capacity in relation to functional characteristics in diabetic patients affected by asthma.

The 3 groups in the trial

  • G1 Asthma

    Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10

    Treatment: data collection

  • G2 Diabetes

    Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c \< 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10

    Treatment: data collection

  • G3 Asthma plus diabetes

    Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c \< 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10

    Treatment: data collection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 February 2024